August 29, 2024
Launching a Product in Europe: Understanding Supply Chain Cost Drivers
Supply Chain Cost Analysis, European Market, Cost Drivers, Supply Chain Management, Risk Management
Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?
Catalent, Novo Holdings, acquisition, pharmaceutical industry, revenue boost, dark days, revival
The Post-Chevron Regulatory Landscape: Implications for the FDA and Healthcare Industry
Chevron deference, FDA, regulatory landscape, healthcare industry, Supreme Court ruling, Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Administrative Procedure Act (APA), judicial scrutiny, legal challenges, regulatory implications.
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630
Repare Therapeutics Cuts 25% of Workforce, Preclinical Team Most Affected
Repare Therapeutics, layoffs, preclinical team, R&D prioritization, biotech industry
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist
Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction
Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease
Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar
Regeneron, Sandoz, Eylea, biosimilar, lawsuit, patent infringement
Future-Proofing Healthcare: Inclusive and Protective Patient Strategies
future-proofing, inclusive healthcare, patient-centered care, digital patient experience, data linkage, clinical trials, health and safety programs
House Oversight Chair Demands PBM Executives Correct False Testimonies
PBM Executives, False Testimonies, House Oversight Chair, James Comer, Pharmacy Benefit Managers, Congressional Hearing